PBT 0.00% 4.4¢ prana biotechnology limited

CytRx partial clinical hold removed after 2 months!

  1. 1,847 Posts.
    lightbulb Created with Sketch. 1
    1/20/15 - FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials -(hold placed on 11/24/2014)
    CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites' Institutional Review Boards (IRBs) approve the revised trial protocols.

    "CytRx developed modified study parameters intended to avoid potential risks, while allowing the company to evaluate the therapeutic impact of aldoxorubicin for patients with soft tissue sarcoma, glioblastoma, Kaposi's sarcoma, and small cell lung cancer, among other trials," said Steven A. Kriegsman, Chairman and CEO of CytRx. "Our staff worked closely with the FDA Oncology Division to resolve all partial clinical hold issues as rapidly as possible. We expect enrollment and dosing in the ongoing clinical trials to be back underway soon."

    CytRx currently believes that enrollment rates and timelines for its trials will remain materially unchanged.
 
watchlist Created with Sketch. Add PBT (ASX) to my watchlist
(20min delay)
Last
4.4¢
Change
0.00(0.00%)
Mkt cap $23.62M
Open High Low Value Volume
4.5¢ 4.5¢ 4.4¢ $5.541K 125K

Buyers (Bids)

No. Vol. Price($)
1 38699 4.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.0¢ 5000 1
Last update - 10.37am 19/10/2018 (20 minute delay) ?
PBT (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.